Clinical TopicsGlobal BulletinAll NewsApproval Alert
2 Minute DrillAround the PracticeBetween the LinesBreaking BarriersFace OffFrom All AnglesMeeting of the MindsMorning RoundsOncViewPodcastsReadout 360Sponsored MediaTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Career CenterSubscribe
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Around the Practice
  • Between the Lines
  • Contemporary Concepts
  • Journal
  • OncView
  • Podcasts
  • Readout 360
  • Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
  • Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study Links Sex Hormones to Childhood Cancer

December 1, 1996
Publication
Article
OncologyONCOLOGY Vol 10 No 12
Volume 10
Issue 12

Women who take sex hormones before and during pregnancy are three times more likely to have children who develop cancer, according to researchers at Roswell Park Cancer Institute.

Women who take sex hormones before and during pregnancy are threetimes more likely to have children who develop cancer, accordingto researchers at Roswell Park Cancer Institute.

Epidemiologist Arthur Michalek, phd, associate director of theDepartment of Education, and colleagues report that neuroblastoma,the most common type of childhood cancer, is linked to a mother'suse of sex hormones to increase fertility, control vaginal bleeding,or prevent miscarriages.

Neuroblastoma tumors are generally found in adrenal glands. Althoughcancer among young children is rare, neuroblastoma accounts forone-quarter of all childhood cancers and is diagnosed in about500 children annually.

Previously, the low incidence rate of neuroblastomas preventedthe detailed investigation of risk factors associated with thisdisease.

In the Roswell Park study, the first and largest of its kind,Dr. Michalek and associates compared the results of interviewswith 183 women whose children were diagnosed with neuroblastomaand 372 women with healthy offspring. Those mothers who used sexhormones were more likely to have children who were later diagnosedwith the disease.

Male children appeared to be at higher risk for the disease thanfemales, with an average age at diagnosis of 18 months.

Women who took sex hormones to increase fertility proved to beat greatest risk. "The sizable numbers of case and controlmothers interviewed [increased] the statistical power of thisstudy and enabled the detection of subtle risk differences,"explained Michalek.

Although not addressed in the study, the researchers suggest thatother potential risk factors, such as the routine use of oralcontraceptives, be examined in mothers of children diagnosed withneuroblastoma.

A Surprising Development

In a surprising development, vitamins used during pregnancy seemedto offer the unborn child some protection against cancer. Thedata, however, were based on a mother's self-reported use of vitamins,and this aspect of the investigation requires more controlledstudy, Michalek noted.

Articles in this issue

One in Three Newly Diagnosed Cancer Patients Now Receives Radiation Therapy
Study Links Sex Hormones to Childhood Cancer
Scientists Confirm Natural Resistance to HIV-1
US Prostate Cancer Rates Dropping for White Men; Stabilizing for African-American Men
NCI's Largest Cancer Screening Trial Now Enrolling Men and Women Ages 55 to 74
Radiation After Lumpectomy for Node-Negative Breast Cancer Reduces Disease Recurrence But Not Overall Mortality
Breast Cancer Incidence and Mortality--United States, 1992
Neurex Presents SNX-111 Chronic Pain Study Results at 15th Annual American Pain Society
Chemotherapy Plus Radiation Improves Prognosis of Nasopharyngeal Carcinoma
New Study Proves Benefits of Antiseptic-Impregnated Catheters
IOM Undertakes Study of Cancer and Minorities
Success of Sentinel Lymph Node Biopsy in Melanoma Leads to Test in Breast Cancer
PET Scanning Improves Treatment of Esophageal Cancer, University of Pittsburgh Study Finds
Cancer Gene Theory Challenged
National Cancer Policy Board to be Establish
Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Related Content
Advertisement

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Consolidative Thoracic Radiotherapy Improves Survival in ES-SCLC

Roman Fabbricatore
April 18th 2025
Article

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.


Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

Classification System May Identify QOL Benefit with Palliative Radiotherapy

Roman Fabbricatore
April 18th 2025
Article

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Optimizing Radiosurgery for CNS Tumors, Insights on Technology and Teamwork

Optimizing Radiosurgery for CNS Tumors, Insights on Technology and Teamwork

Ariana Pelosci
April 18th 2025
Article

William Kennedy, MD, discussed modern radiosurgery techniques, technology selection, and the multidisciplinary approach for treating complex CNS tumors.


Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC

Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC

Tim Cortese
April 18th 2025
Article

Pooled results from the TRUST-I and TRUST-II trials showed that taletrectinib led to infrequent neurological TEAEs in patients with ROS1-positive NSCLC.

Related Content
Advertisement

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Consolidative Thoracic Radiotherapy Improves Survival in ES-SCLC

Roman Fabbricatore
April 18th 2025
Article

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.


Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

Classification System May Identify QOL Benefit with Palliative Radiotherapy

Roman Fabbricatore
April 18th 2025
Article

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Optimizing Radiosurgery for CNS Tumors, Insights on Technology and Teamwork

Optimizing Radiosurgery for CNS Tumors, Insights on Technology and Teamwork

Ariana Pelosci
April 18th 2025
Article

William Kennedy, MD, discussed modern radiosurgery techniques, technology selection, and the multidisciplinary approach for treating complex CNS tumors.


Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC

Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC

Tim Cortese
April 18th 2025
Article

Pooled results from the TRUST-I and TRUST-II trials showed that taletrectinib led to infrequent neurological TEAEs in patients with ROS1-positive NSCLC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.